Exact Mass: 441.2336
Exact Mass Matches: 441.2336
Found 500 metabolites which its exact mass value is equals to given mass value 441.2336
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Leukotriene E3
Leukotriene E3 is an eicosanoid derived from 8,11,14-Eicosatrienoic acid by the 5-Lipoxygenase-Leukotriene Pathway. The eicosanoids are a diverse family of molecules that have powerful effects on cell function. They are best known as intercellular messengers, having autocrine and paracrine effects following their secretion from the cells that synthesize them. The diversity of possible products that can be synthesized from eicosatrienoic acid is due, in part to the variety of enzymes that can act on it. Studies have placed many, but not all, of these enzymes at or inside the nucleus. In some cases, the nuclear import or export of eicosatrienoic acid-processing enzymes is highly regulated. Furthermore, nuclear receptors that are activated by specific eicosanoids are known to exist. Taken together, these findings indicate that the enzymatic conversion of eicosatrienoic acid to specific signaling molecules can occur in the nucleus, that it is regulated, and that the synthesized products may act within the nucleus. Leukotriene E3 is also a by-product of the metabolism of leukotriene C3. Although they are primarily known for their roles in asthma, pain, fever and vascular responses, present evidence indicates that eicosanoids exert relevant effects on immune/inflammatory, as well as structural, cells pertinent to fibrogenesis. (PMID: 7306127, 8142566, 16574479, 15896193)Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. Leukotriene E3 is an eicosanoid derived from 8,11,14-Eicosatrienoic acid by the 5-Lipoxygenase-Leukotriene Pathway. The eicosanoids are a diverse family of molecules that have powerful effects on cell function. They are best known as intercellular messengers, having autocrine and paracrine effects following their secretion from the cells that synthesize them. The diversity of possible products that can be synthesized from eicosatrienoic acid is due, in part to the variety of enzymes that can act on it. Studies have placed many, but not all, of these enzymes at or inside the nucleus. In some cases, the nuclear import or export of eicosatrienoic acid-processing enzymes is highly regulated. Furthermore, nuclear receptors that are activated by specific eicosanoids are known to exist. Taken together, these findings indicate that the enzymatic conversion of eicosatrienoic acid to specific signaling molecules can occur in the nucleus, that it is regulated, and that the synthesized products may act within the nucleus. Leukotriene E3 is also a by-product of the metabolism of leukotriene C3. Although they are primarily known for their roles in asthma, pain, fever and vascular responses, present evidence indicates that eicosanoids exert relevant effects on immune/inflammatory, as well as structural, cells pertinent to fibrogenesis. (PMID: 7306127, 8142566, 16574479, 15896193)
Vilazodone
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. It has been shown to be equally efficacious as other antidepressants with similar gastrointestinal side effects and possibly with reduced sexual side effects and weight gain. Vilazodone is an antidepressant agent that can used as an alternative for patients who cannot tolerate therapy with other antidepressant classes such as selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. Treatment should be titrated towards the target dose, which is 40mg per day. D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active?serotonin?reuptake inhibitor (SSRI) and partial?5-HT1A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders[1][2].
3-N-(2-Fluoroethyl)spiperone
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D019275 - Radiopharmaceuticals
Pentanoic acid, 5-(dipentylamino)-5-oxo-4-((3-quinolinylcarbonyl)amino)-, (R)-
Bacmecillinam
Cerivastatin lactone
Deflazacort
4-(2-((4-(2-(Pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethyl)morpholine
Ergomet
Ergometrine maleate is a maleate salt resulting form the reaction of equimolar amounts of maleic acid and ergometrine. It is used in the active management of the third stage of labour, and to prevent or treat postpartum of postabortal haemorrhage caused by uterine atony: by maintaining uterine contraction and tone, blood vessels in the uterine wall are compressed and blood flow reduced. It has a role as an oxytocic and a diagnostic agent. It contains an ergometrine. An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties. C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D012102 - Reproductive Control Agents > D010120 - Oxytocics
Floridanine
A pyrrolizine alkaloid that is onetine in which the hydroxy hydrogen has been replaced by an acetyl group. Origin: Plant; SubCategory_DNP: Alkaloids derived from ornithine, Pyrrolizidine alkaloids
(13R)-11alpha-acetoxy-2alpha-hydroxy-13-isobutyryloxyhetisane|trichodelphinine A
Ser His Ala Lys
Ala His Lys Ser
Ala His Asn Thr
Ala His Gln Ser
Ala His Ser Lys
Ala His Ser Gln
Ala His Thr Asn
Ala Lys His Ser
Ala Lys Ser His
Ala Asn His Thr
Mebeverine metabolite (1-Butanol, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]- glucuronide)
Ala Asn Thr His
Ala Pro Arg Val
Ala Pro Val Arg
Ala Gln His Ser
Ala Gln Ser His
Ala Arg Pro Val
Ala Arg Val Pro
Ala Ser His Lys
Ala Ser His Gln
Ala Ser Lys His
Ala Ser Gln His
Ala Thr His Asn
Ala Thr Asn His
Ala Val Pro Arg
Ala Val Arg Pro
Gly His Lys Thr
Gly His Gln Thr
Gly His Thr Lys
Gly His Thr Gln
Gly Ile Pro Arg
Gly Ile Arg Pro
Gly Lys His Thr
Gly Lys Thr His
Gly Leu Pro Arg
Gly Leu Arg Pro
Gly Pro Ile Arg
Gly Pro Leu Arg
Gly Pro Arg Ile
Gly Pro Arg Leu
Gly Gln His Thr
Gly Gln Thr His
Gly Arg Ile Pro
Gly Arg Leu Pro
Gly Arg Pro Ile
Gly Arg Pro Leu
Gly Thr His Lys
Gly Thr His Gln
Gly Thr Lys His
Gly Thr Gln His
His Ala Lys Ser
His Ala Asn Thr
His Ala Gln Ser
His Ala Ser Lys
His Ala Ser Gln
His Ala Thr Asn
His Gly Lys Thr
His Gly Gln Thr
His Gly Thr Lys
His Gly Thr Gln
His Lys Ala Ser
His Lys Gly Thr
His Lys Ser Ala
His Lys Thr Gly
His Asn Ala Thr
His Asn Thr Ala
His Gln Ala Ser
His Gln Gly Thr
His Gln Ser Ala
His Gln Thr Gly
His Ser Ala Lys
His Ser Ala Gln
His Ser Lys Ala
His Ser Gln Ala
His Thr Ala Asn
His Thr Gly Lys
His Thr Gly Gln
His Thr Lys Gly
His Thr Asn Ala
His Thr Gln Gly
Ile Gly Pro Arg
Ile Gly Arg Pro
Ile Asn Pro Val
Ile Asn Val Pro
Ile Pro Gly Arg
Ile Pro Asn Val
Ile Pro Arg Gly
Ile Pro Val Asn
Ile Arg Gly Pro
Ile Arg Pro Gly
Ile Val Asn Pro
Ile Val Pro Asn
Lys Ala His Ser
Lys Ala Ser His
Lys Gly His Thr
Lys Gly Thr His
Lys His Ala Ser
Lys His Gly Thr
Lys His Ser Ala
Lys His Thr Gly
Lys Pro Pro Thr
Lys Pro Thr Pro
Lys Ser Ala His
Lys Ser His Ala
Lys Thr Gly His
Lys Thr His Gly
Lys Thr Pro Pro
Leu Gly Pro Arg
Leu Gly Arg Pro
Leu Asn Pro Val
Leu Asn Val Pro
Leu Pro Gly Arg
Leu Pro Asn Val
Leu Pro Arg Gly
Leu Pro Val Asn
Leu Arg Gly Pro
Leu Arg Pro Gly
Leu Val Asn Pro
Leu Val Pro Asn
Asn Ala His Thr
Asn Ala Thr His
Asn His Ala Thr
Asn His Thr Ala
Asn Ile Pro Val
Asn Ile Val Pro
Asn Leu Pro Val
Asn Leu Val Pro
Asn Pro Ile Val
Asn Pro Leu Val
Asn Pro Val Ile
Asn Pro Val Leu
Asn Thr Ala His
Asn Thr His Ala
Asn Val Ile Pro
Asn Val Leu Pro
Asn Val Pro Ile
Asn Val Pro Leu
Pro Ala Arg Val
Pro Ala Val Arg
Pro Gly Ile Arg
Pro Gly Leu Arg
Pro Gly Arg Ile
Pro Gly Arg Leu
Pro Ile Gly Arg
Pro Ile Asn Val
Pro Ile Arg Gly
Pro Ile Val Asn
Pro Lys Pro Thr
Pro Lys Thr Pro
Pro Leu Gly Arg
Pro Leu Asn Val
Pro Leu Arg Gly
Pro Leu Val Asn
Pro Asn Ile Val
Pro Asn Leu Val
Pro Asn Val Ile
Pro Asn Val Leu
Pro Pro Lys Thr
Pro Pro Gln Thr
Pro Pro Thr Lys
Pro Pro Thr Gln
Pro Gln Pro Thr
Pro Gln Thr Pro
Pro Gln Val Val
Pro Arg Ala Val
Pro Arg Gly Ile
Pro Arg Gly Leu
Pro Arg Ile Gly
Pro Arg Leu Gly
Pro Arg Val Ala
Pro Thr Lys Pro
Pro Thr Pro Lys
Pro Thr Pro Gln
Pro Thr Gln Pro
Pro Val Ala Arg
Pro Val Ile Asn
Pro Val Leu Asn
Pro Val Asn Ile
Pro Val Asn Leu
Pro Val Gln Val
Pro Val Arg Ala
Pro Val Val Gln
Gln Ala His Ser
Gln Ala Ser His
Gln Gly His Thr
Gln Gly Thr His
Gln His Ala Ser
Gln His Gly Thr
Gln His Ser Ala
Gln His Thr Gly
Gln Pro Pro Thr
Gln Pro Thr Pro
Gln Pro Val Val
Gln Ser Ala His
Gln Ser His Ala
Gln Thr Gly His
Gln Thr His Gly
Gln Thr Pro Pro
Gln Val Pro Val
Gln Val Val Pro
Arg Ala Pro Val
Arg Ala Val Pro
Arg Gly Ile Pro
Arg Gly Leu Pro
Arg Gly Pro Ile
Arg Gly Pro Leu
Arg Ile Gly Pro
Arg Ile Pro Gly
Arg Leu Gly Pro
Arg Leu Pro Gly
Arg Pro Ala Val
Arg Pro Gly Ile
Arg Pro Gly Leu
Arg Pro Ile Gly
Arg Pro Leu Gly
Arg Pro Val Ala
Arg Val Ala Pro
Arg Val Pro Ala
Ser Ala His Lys
Ser Ala His Gln
Ser Ala Lys His
Ser Ala Gln His
Ser His Ala Gln
Ser His Lys Ala
Ser His Gln Ala
Ser Lys Ala His
Ser Lys His Ala
Ser Gln Ala His
Ser Gln His Ala
Thr Ala His Asn
Thr Ala Asn His
Thr Gly His Lys
Thr Gly His Gln
Thr Gly Lys His
Thr Gly Gln His
Thr His Ala Asn
Thr His Gly Lys
Thr His Gly Gln
Thr His Lys Gly
Thr His Asn Ala
Thr His Gln Gly
Thr Lys Gly His
Thr Lys His Gly
Thr Lys Pro Pro
Thr Asn Ala His
Thr Asn His Ala
Thr Pro Lys Pro
Thr Pro Pro Lys
Thr Pro Pro Gln
Thr Pro Gln Pro
Thr Gln Gly His
Thr Gln His Gly
Thr Gln Pro Pro
Val Ala Pro Arg
Val Ala Arg Pro
Val Ile Asn Pro
Val Ile Pro Asn
Val Leu Asn Pro
Val Leu Pro Asn
Val Asn Ile Pro
Val Asn Leu Pro
Val Asn Pro Ile
Val Asn Pro Leu
Val Pro Ala Arg
Val Pro Ile Asn
Val Pro Leu Asn
Val Pro Asn Ile
Val Pro Asn Leu
Val Pro Gln Val
Val Pro Arg Ala
Val Pro Val Gln
Val Gln Pro Val
Val Gln Val Pro
Val Arg Ala Pro
Val Arg Pro Ala
Val Val Pro Gln
Val Val Gln Pro
Leukotriene E3
A leukotriene that is leukotriene E4 in which the non-conjugated double bond has been reduced to a single bond.
Vilazodone
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D049990 - Membrane Transport Modulators Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active?serotonin?reuptake inhibitor (SSRI) and partial?5-HT1A receptor agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders[1][2].
N,N-ethylenebis[N-(carboxymethyl)glycine], compound with 2,2,2-nitrilotri(ethanol)
3H-Indolium, 2-2-(4,5-dihydro-3,5-diphenyl-1H-pyrazol-1-yl)ethenyl-1,3,3-trimethyl-, chloride
LY2109761
6-[2-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-di(propan-2-yl)pyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one
Deflazacort
H - Systemic hormonal preparations, excl. sex hormones and insulins > H02 - Corticosteroids for systemic use > H02A - Corticosteroids for systemic use, plain > H02AB - Glucocorticoids C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000893 - Anti-Inflammatory Agents
3-Hydroxy-piperidine-1-carboxylic acid tert-butyl ester
2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid,2-[bis(2-hydroxyethyl)amino]ethanol
N-(1-Carboxy-3-phenylpropyl)phenylalanyl-alpha-asparagine
Bisoprolol monofumarate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
5-Methyl-3-(9-oxo-1,8-diaza-tricyclo[10.6.1.013,18]nonadeca-12(19),13,15,17-tetraen-10-ylcarbamoyl)-hexanoic acid
N-(4-Morpholine)carbonyl-B-(1-naphthyl)-L-alanine-L-leucine boronic acid
Lisinopril diydrate
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D000806 - Angiotensin-Converting Enzyme Inhibitors C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C247 - ACE Inhibitor D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents
Ergonovine maleate
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66884 - Dopamine Agonist D012102 - Reproductive Control Agents > D010120 - Oxytocics
[(2S,3R,4R,6R)-3-hydroxy-2-methyl-6-(12-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)oxan-4-yl]azanium
6-[2-[4-(4-Fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)-3-pyridyl]vinyl]-4-hydroxy-tetrahydropyran-2-one
(3S)-3-(1,3-benzodioxol-5-yl)-1-(3,5-dimethyl-1-piperidinyl)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-propanone
(2S)-2-[[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoic acid
5,7-Dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxylic acid [2-[2-(3,4-diethoxyphenyl)ethylamino]-2-oxoethyl] ester
3-[[2-[[(2-Methylpropan-2-yl)oxy-oxomethyl]amino]-1-oxoethyl]hydrazo]-3-oxo-2-phenylpropanoic acid (phenylmethyl) ester
Lys-Thr-Pro-Pro
A tetrapeptide composed of L-lysine, L-threonine and two L-proline units joined in sequence by peptide linkages.
3alpha,7alpha-Dihydroxy-5beta-cholane-24-sulfonate
D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids
(1R,4S,6R,7R,11Z)-4-hydroxy-4-[(1R)-1-hydroxyethyl]-6,7,14-trimethyl-3,8,17-trioxo-2,9-dioxa-14-azabicyclo[9.5.1]heptadec-11-en-7-yl acetate
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide
(1R,9S,10S,11S)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-N,N-dimethyl-12-(oxan-4-ylmethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxyacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(pyridin-3-ylmethyl)acetamide
(2S,3R)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3R)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(2-methoxyphenyl)-3-methyl-2-[[methyl(propyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-2-[[(4-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-8-methylsulfonyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
N-(1,3-benzodioxol-5-ylmethyl)-2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[1-oxo-2-(3-pyridinyl)ethyl]amino]-2-oxanyl]acetamide
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(3-pyridinylmethyl)acetamide
(2R,3R)-2-(hydroxymethyl)-1-(oxane-4-carbonyl)-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazaspiro[3.3]heptane-6-carboxamide
(2S,3S)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3S)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2S,3R)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
(2R,3S)-2-[[(2-fluorophenyl)methyl-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-5-methylsulfonyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-propyl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5S,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-pyrazinecarboxamide
N-[(5R,6S,9S)-5-methoxy-3,6,9-trimethyl-8-methylsulfonyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-8-methylsulfonyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]acetamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-propyl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]methanesulfonamide
N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]-3-oxanyl]-2-methoxybenzenesulfonamide
2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1R)-1-phenylethyl]acetamide
2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[[(2-methoxyanilino)-oxomethyl]amino]-2-oxanyl]-N-[(1S)-1-phenylethyl]acetamide
(1S,9R,10R,11R)-5-(cyclopenten-1-yl)-10-(hydroxymethyl)-N,N-dimethyl-12-(oxan-4-ylmethyl)-6-oxo-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
[(1R)-1-[(2,5-difluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1S)-1-[(2,5-difluorophenyl)methyl]-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
(2S,3R)-2-(hydroxymethyl)-1-(oxane-4-carbonyl)-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazaspiro[3.3]heptane-6-carboxamide
2-Amino-3-[(3-dodecanoyloxy-2-hydroxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-[2,3-Di(trimethylsilyloxy)butoxy]-N-[2-(ethylamino)ethyl]-3-pyridinecarboxamide
T0467
T0467 activates parkin mitochondrial translocation in a PINK1-dependent manner in vitro. T0467 do not induce mitochondrial accumulation of PINK1in dopaminergic neurons. T0467 is a potential compound for PINK1-Parkin signaling activation, and can be used for parkinson's disease and related disorders research[1].